Trading update

RNS Number : 7125E
Diaceutics PLC
08 July 2019
 

8 July 2019

 

Diaceutics PLC

("Diaceutics" or the "Company")

 

Trading update

 

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces a trading update for the six months ended 30 June 2019.  Trading has continued in line with market expectations and the Company remains well positioned in key markets, underpinned by a strong sales performance. 

 

An increased international footprint has enhanced Diaceutics' global offering and allowed the Company to acquire new international clients.  The Nexus project is progressing as planned.

 

All outstanding debt has now been retired from the balance sheet resulting in net cash of £14.0m.

 

The Group's interim results are expected to be announced in early September. 

 

Enquiries:

 

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer

 

 

 

Cenkos Securities plc (Nominated adviser and broker)

+44 (0) 20 3861 6630

Callum Davidson / Giles Balleny

 

Michael Johnson (Sales)

 

 

 

Walbrook PR

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893

 

 

 

 

 

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies.  The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing.  By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes.  The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects.  The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.  www.diaceutics.com 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUGUQAMUPBURQ

Companies

Diaceutics (DXRX)
UK 100